MNKD

Mannkind

4.520

+0.470+11.60%

After Hours: 4.500 -0.020 -0.44%19:51 07/02 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE4.095/4.050

TODAY RANGE4.080-4.545

VOL9.57M

MARKET CAP1.40B

52 WEEK RANGE2.230-6.51

AVG VOL (3M)5.56M

% TURNOVER3.10%

TURNOVER--

P/E (TTM)-59.7094

% RANGE11.38%

EPS(TTM)-0.0757

P/E(FORWARD)-150.6667

P/B-23.5908

BVPS-0.1916

DIVIDEND--

P/S3.987

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP1.35B

SHARES OUTSTANDING308.95M

NEXT EARNINGS08/04-08/10

FREE FLOAT298.04M

LOT SIZE1

EX-DATE03/03/2017

News

Press Releases

Financial Reports

Profile

NASDAQ·3d ago
Biotech Stocks Facing FDA Decision In July 2026
Reuters·06/23 13:06
MANNKIND AWARDED BREAKTHROUGH T1D GRANT TO SUPPORT ADVANCEMENT OF INHALE-1ST PEDIATRIC TRIAL OF AFREZZA® IN YOUTH WITH NEWLY-DIAGNOSED T1D
Benzinga·06/23 13:03
MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients
PUBT·06/23 13:00
MannKind wins Breakthrough T1D grant for INHALE-1ST pediatric Afrezza trial
NASDAQ·06/08 08:59
Mankind: Afreezza Data At ADA 2026 Underscores Pediatric Safety And Expands Use In Diabetes Care
Benzinga·06/08 07:44
Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval
Benzinga·06/05 12:05
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends
TipRanks·06/03 10:15
MannKind announces milestones in development of nintedanib DPI for IPF
Benzinga·06/03 10:11
MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis
PUBT·06/03 10:05
MannKind enrolls first patient in Phase 2 INFLO-2 trial of inhaled nintedanib for IPF
Reuters·06/03 10:05
MANNKIND - EXPECTS PHASE 1B INFLO-1 DATA READOUT IN Q3 2026
TipRanks·06/03 09:40
Wall Street Analysts Are Bullish on Top Healthcare Picks
Seeking Alpha·06/03 02:40
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
TipRanks·06/02 12:42
MannKind Gains FDA Approval for Afrezza Pediatric Use
PUBT·06/02 12:06
MannKind says FDA approves Afrezza for children aged 6 and older with diabetes

Same Industry

Name/Symbol

Change%

Price

MNKD

Regeneron Pharmaceuticals

REGN

+4.73%

654.27

GridAI Tech

GRDX

+1.85%

4.410

BNTX

United Therapeutics Corp.

UTHR

+0.42%

544.92

Vertex Pharmaceuticals Inc

VRTX

+6.03%

528.04

Siga Technologie

SIGA

+3.76%

3.860

Moderna

MRNA

-0.54%

69.33

Charles Riv Labs Intl Inc

CRL

+0.70%

230.69

Medpace Holdings

MEDP

+1.37%

527.07

Talphera Inc

TLPH

-3.74%

1.030

China Biologic

CBPO

0.00%

119.99

ICON plc

ICLR

-1.14%

173.06

Iqvia Hldgs Inc

IQV

+2.53%

191.14

MOLECULAR PARTNERS AG

MOLN

+1.55%

3.930

PRA Health

PRAH

0.00%

165.21

Gilead Sciences Inc

GILD

-1.21%

126.33

Arcturus Therape

ARCT

+0.88%

6.88

INCY

Aptevo Therapeutics Inc

APVO

+0.23%

4.450

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.